Genentech is voluntarily recalling the Susvimo implant and insertion tool for the treatment of wet age-related macular degeneration in the U.S., according to a company statement.
In addition, new implantations of Susvimo (ranibizumab injection), including those taking place in ongoing clinical trials, have been paused.
The recall is based on recent commercial supply testing in which implants were exposed to repeated puncturing with a needle and did not perform to company standards.
However, there is no medical need to remove Susvimo in patients already implanted with it. The recall does not